Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance after allogeneic HSCT in MDS or AML with chromosome 5 abnormalities
2007-002433-37Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoint: Cumulative incidence of relapse at 1 year post transplantation. Started Oct 2007; status: terminated.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-002433-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002433-37.